Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard M Trosch

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Neurology|April 6, 2016
Physicians' experience with RYTARY (carbidopa and levodopa) extended-release capsules in patients who have Parkinson diseaseDee E Silver, Richard M Trosch
CNS Drugs|May 20, 2008
Intermittent subcutaneous apomorphine therapy for 'off' episodes in Parkinson's disease: a 6-month open-label studyRichard M Trosch, Dee Silver, Peter B Bottini
Movement Disorders : Official Journal of the Movement Disorder Society|June 26, 2007
Botulinum toxin type B (Myobloc) in subjects with hemifacial spasm: results from an open-label, dose-escalation safety studyRichard M Trosch, Charles H Adler, Eric J Pappert
Journal of Clinical Movement Disorders|July 14, 2018
Spectrum of practice in the routine management of cervical dystonia with abobotulinumtoxinA: findings from three prospective open-label observational studiesVijay P Misra, Richard M Trosch, Pascal Maisonobe, et al.
Expert Review of Neurotherapeutics|September 27, 2021
Pain in cervical dystonia: mechanisms, assessment and treatmentRaymond L Rosales, Lorraine Cuffe, Benjamin Regnault, et al.
Journal of the Neurological Sciences|May 1, 2007
Subcutaneous apomorphine in patients with advanced Parkinson's disease: a dose-escalation study with randomized, double-blind, placebo-controlled crossover evaluation of a single doseRajesh Pahwa, William C Koller, Richard M Trosch, et al.
Clinical Parkinsonism & Related Disorders|July 28, 2021
Impact of abobotulinumtoxinA on the clinical features of cervical dystonia in routine practiceRichard M Trosch, Vijay P Misra, Pascal Maisonobe, et al.
Journal of Managed Care & Specialty Pharmacy|September 25, 2015
A Retrospective, Single-Center Comparative Cost Analysis of OnabotulinumtoxinA and AbobotulinumtoxinA for Cervical Dystonia TreatmentRichard M Trosch, Alicia C Shillington, Marci L English, et al.
JAMA Neurology|January 14, 2020
Safety and Efficacy of RimabotulinumtoxinB for Treatment of Sialorrhea in Adults: A Randomized Clinical TrialStuart H Isaacson, William Ondo, Carlayne E Jackson, et al.
Parkinsonism & Related Disorders|April 5, 2025
A validation study of the Clinician's Tardive Inventory (CTI)Richard M Trosch, Alicia C Shillington, Cynthia L Comella, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Neurology|April 6, 2016
Physicians' experience with RYTARY (carbidopa and levodopa) extended-release capsules in patients who have Parkinson diseaseDee E Silver, Richard M Trosch
CNS Drugs|May 20, 2008
Intermittent subcutaneous apomorphine therapy for 'off' episodes in Parkinson's disease: a 6-month open-label studyRichard M Trosch, Dee Silver, Peter B Bottini
Movement Disorders : Official Journal of the Movement Disorder Society|June 26, 2007
Botulinum toxin type B (Myobloc) in subjects with hemifacial spasm: results from an open-label, dose-escalation safety studyRichard M Trosch, Charles H Adler, Eric J Pappert
Journal of Clinical Movement Disorders|July 14, 2018
Spectrum of practice in the routine management of cervical dystonia with abobotulinumtoxinA: findings from three prospective open-label observational studiesVijay P Misra, Richard M Trosch, Pascal Maisonobe, et al.
Expert Review of Neurotherapeutics|September 27, 2021
Pain in cervical dystonia: mechanisms, assessment and treatmentRaymond L Rosales, Lorraine Cuffe, Benjamin Regnault, et al.
Journal of the Neurological Sciences|May 1, 2007
Subcutaneous apomorphine in patients with advanced Parkinson's disease: a dose-escalation study with randomized, double-blind, placebo-controlled crossover evaluation of a single doseRajesh Pahwa, William C Koller, Richard M Trosch, et al.
Clinical Parkinsonism & Related Disorders|July 28, 2021
Impact of abobotulinumtoxinA on the clinical features of cervical dystonia in routine practiceRichard M Trosch, Vijay P Misra, Pascal Maisonobe, et al.
Journal of Managed Care & Specialty Pharmacy|September 25, 2015
A Retrospective, Single-Center Comparative Cost Analysis of OnabotulinumtoxinA and AbobotulinumtoxinA for Cervical Dystonia TreatmentRichard M Trosch, Alicia C Shillington, Marci L English, et al.
JAMA Neurology|January 14, 2020
Safety and Efficacy of RimabotulinumtoxinB for Treatment of Sialorrhea in Adults: A Randomized Clinical TrialStuart H Isaacson, William Ondo, Carlayne E Jackson, et al.
Parkinsonism & Related Disorders|April 5, 2025
A validation study of the Clinician's Tardive Inventory (CTI)Richard M Trosch, Alicia C Shillington, Cynthia L Comella, et al.
Pageof 2